It is without a doubt that 2020 brought forth many challenges, not least those concerning the economy.
Fortunately, there has been plenty of good news coming out of the European space during the same period;
1. The European Court of Justice ruling on the Kanavape case, which stated that CBD was not a narcotic drug, therefore allowing the free movement of the substance between EU member states,
2. The United Nations removing cannabis from Schedule IV of the 1961 Single Convention on Narcotic Drugs.
Stateside, we had the House of Representatives make a historic statement by voting in favour of the MORE Act, which would decriminalise cannabis and erase nonviolent federal marijuana convictions, even though it was unlikely to pass the Senate and be ratified.
Other background information
However, with the inauguration of the United States’ 46th President, Joe Biden, bullish sentiment around the question of federal legalisation has continued to take hold across the country. Many states already have some form of legalisation, be it medical or recreational. However, cannabis being Federally illegal means that companies selling the drug and individuals who consume the drug, both medicinally and recreationally, are not allowed to cross state lines with it.
In addition, this past Monday, Senate Majority Leader Chumer (D-NY), Senate Finance Committee Chairman Ron Wyden (D-OR) and Sen. Cory Booker (D-NJ) said in a joint statement that ending cannabis prohibition "is necessary to right the wrongs of this failed war and end decades of harm inflicted on communities of colour across the country", and that they were "committed to working together to put forward and advance comprehensive cannabis reform legislation that will not only turn the page on this sad chapter in American history, but also undo the devastating consequences of these discriminatory policies", they said. "The Senate will make consideration of these reforms a priority".
No doubt 2021 will be the year where many countries around the globe will look to the United States for direction, as they have in the past, on how to amend their own regulations surrounding the drug.
We offer a free consultation. Please contact us here.